Search News Archives
Special Offers and Promotions
Conferences | Events
PerkinElmer Unveils Advanced Drug Discovery and Disease Research Solutions at SLAS2020
Workstations and high-content screening system automate workflows to help researchers generate invaluable insights
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has introduced new workstations and a high content screening system at SLAS2020 in San Diego. These technologies automate workflows so that disease research and drug discovery professionals can improve productivity, increase reproducibility, and garner key insights.
PerkinElmer highlighted these new systems, along with several key offerings from its comprehensive portfolio of instruments and reagents at SLAS2020:
- JANUS® G3 Blood iQ™ Workstation: for biobanking workflows, it offers front end reformatting of plasma and buffy coat layers from centrifuged blood tubes, enabling highly reproducible, downstream genetic analysis.
- Sciclone® G3 NGSx HT Workstation: helps simplify the miniaturization of NGS library prep. Coupled with a new NEXTFLEX® Rapid XP DNA-seq kit, this library preparation workflow is designed to enable researchers to increase their NGS throughput while decreasing their cost per reaction.
- Opera Phenix® Plus High Content Screening System: for fast response analysis of physiologically relevant model systems, this enhancement to PerkinElmer’s high content imaging platform adds fast frame rate image capture for assays such as cardiomyocyte beat rate monitoring. It also offers an optional liquid handling module to enable assays like Ca2+ flux, important to the study of neurological diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Designed to drive more relevant testing earlier in the drug discovery process, the Opera Phenix Plus system can also be used with two cell cultures, primary cells, 3D organoids, spheroids and microtissues.
PerkinElmer also showcased additional technologies that enable disease research and life sciences: LabChip® GX Touch™ Nucleic Acid Analyzer; explorer™ G3 Integrated Workstations; MuviCyte™ Live-Cell Imaging Kit; VICTOR® Nivo™ Multimode Microplate Reader; EnVision® Multimode Plate Reader; and EnSight™ Multimode Plate Reader.
SLAS attendees heard about PerkinElmer’s industry-leading no-wash assay technologies including the Alpha, LANCE® Ultra™ and HTRF® assays. The Alpha CETSA® assays combine PerkinElmer’s Alpha and Pelago Biosciences' Cellular Thermal Shift assays (CETSA®), which enable the assessment of target engagement in cell-based assays and generate more physiologically-relevant results.
These products are for research use only. Not for use in diagnostic procedures.
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.8 billion in 2018, serves customers in more than 180 countries, and is a component of the S&P 500 index.